Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06561230 · ClinicalTrials.gov registry record
Leveraging EA8191 to Assess AI-Augmented EHR Abstraction
A clinical trial of Prostate Cancer, sponsored by University of Pennsylvania.
- Active
- Registry status
- 300
- Enrollment target
- 1
- Study location
NCT06561230: Active study of Prostate Cancer, sponsored by University of Pennsylvania.
NCT06561230 is a study of Prostate Cancer that is active but no longer recruiting, run by University of Pennsylvania. The registered enrollment target is 300 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (51% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06561230, a study of Prostate Cancer, is active but no longer recruiting, sponsored by University of Pennsylvania.
- ACTIVE NOT RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this prospective study is to assess the performance of AI (artificial intelligence) augmentation (compared against historical controls) to identify oncology patients who meet inclusion criteria for a clinical trial. The study staff will leverage a natural language processing (NLP)-based AI algorithm that rank-orders patients most likely to meet inclusion criteria for a trial. We hypothesize that this collaborative Human+AI workflow can improve the efficiency, accuracy, and diversity of trial prescreening.
Primary Outcome
The number of eligible patients per 10 charts prescreened
Conditions Studied
Interventions
- OTHER Chart review
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2025-04-04 |
| Est. Completion | 2026-08 |
What the registry record for NCT06561230 still lists
NCT06561230 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (51% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Chart review is the first listed.
NCT06561230 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06561230 about?
NCT06561230 is a clinical study titled "Leveraging EA8191 to Assess AI-Augmented EHR Abstraction". The goal of this prospective study is to assess the performance of AI (artificial intelligence) augmentation (compared against historical controls) to identify oncology patients who meet inclusion criteria for a clinical trial. The study staff will leverage a natural language processing (NLP)-based ...
What is the current status of trial NCT06561230?
This trial is currently active not recruiting. The enrollment target is 300 participants. The study started on 2025-04-04. Estimated completion is 2026-08.
What conditions does trial NCT06561230 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT06561230?
The interventions under investigation include: Chart review (OTHER).
Who is sponsoring clinical trial NCT06561230?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06561230 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06561230's enrollment target sits among peer trials
300 159th of 735 higher than 569 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy
RECRUITING
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
- NCT01266577 · 300 participants · NA
Development of Magnetic Resonance Spectroscopic Imaging Techniques for Imaging Metabolites in Human Brain and Muscle
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI